Business
INTIVA BioPharma (OTCQB: NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE)
INTIVA BioPharma (OTCQB: NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE).
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"The CSE Listing, When Approved, Will Increase Intiva Biopharma's Visibilty in the International Financial Community and Help Attract Interest from Global InvestorsDENVER, CO / ACCESSWIRE / August 22, 2018 / INTIVA BioPharma Inc. (\"INTIVA\" or the \"Company\") (OTCQB: NTVA) announced today that it has filed a preliminary non-offering prospectus with certain securities regulators in Canada and has filed a listing application to list its common shares with the Canadian Securities Exchange (\"CSE\"). Intiva BioPharma's shares currently trade on the OTCQB market in the United States, and upon approval of the CSE listing will trade both in the U.S. and Canada.In announcing the CSE listing application, Alain Bankier, INTIVA BioPharma's Interim CEO, said, \"Cannabinoid pharmaceutical development is increasingly becoming a global activity. Consistent with this trend, we recently announced that Germany-based, Dr. Benedikt Schoser was retained as an advisor to INTIVA. Dr. Schoser is a world-renowned expert on the molecular mechanisms of muscle loss and weakness, and myotonic dystrophy, conditions for which INTIVA previously filed a patent application in the U.S.\"Bankier also stated, \"Since Toronto has become the world financial center for cannabis and cannabinoid pharma-related financings, it became clear that a Canadian stock market listing would be beneficial for INTIVA in potentially accessing capital from global investors and developing increased trading activity of the Company's shares.\"About INTIVA BioPharma Inc:INTIVA BioPharma is a US-based pharmaceutical development company engaged in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (\"FDA\") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.INTIVA BioPharma's drug development strategy consists of: The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; Conducting \"freedom to operate\" investigations on these conditions; The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; Identifying the regulatory pathway with the FDA; and Proceeding with pre-clinical and clinical development activities in accordance with...